



This project received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 953110.



Pharmaceutical Open Innovation Test Bed for Enabling Nano-pharmaceutical Innovative Products

Dr. Nazende Günday-Türeli

Nano2Clinic - Synergies for Clinical Translation of

Nanotechnology in Cancer Therapies

03.03.2023




Specific Challenges

DT-NMBP-06-2020: Open Innovation Test Beds for nano-pharmaceuticals production (IA)

 Many novel promising lab PoC nano-pharmaceuticals across Europe and the world.


- strong potential for providing more effective and safer therapies and diagnostic procedures for a wide range of diseases.

 Major challenge to produce the novel nano-pharmaceuticals to GMP quality in sufficient quantity for late pre-clinical and clinical testing



Specific Challenges

- Main prerequisites for successful implementation: Affordable and advanced testing, manufacturing facilities and services for novel nano-pharmaceuticals
- Difficulties in industrial-scale production in terms of the product quantity and quality required for them entering clinical trials



Nazende Günday-Türeli, Akif Emre Türeli, "Upscaling and GMP Production of Nanopharmaceuticals Drug Delivery Systems" in Drug Delivery Trends: Volume 3: Expectations and Realities of Multifunctional Drug Delivery Systems, edited by Ranjita Shegokar, Elsevier, 2020, p215-23

PHOENIX Consortium

- 12 partners across Europe
- Coming together for 48 months (01.03.2021 – 28.02.2025)
- Sharing project budget of €14.45 million and a requested EU contribution of €11.1 million
- Providing their own resources and services to boost the first implementation phase and PHOENIX-OITB service generation from M1
- Responding to the current and future needs and challenges in bringing the newly developed nano-pharmaceuticals from the bench to the bed side




PHOENIX Consortium

PARTNERS

Our Objective: Enabling Nano-pharmaceutical Innovative Products

PHOENIX bridging the innovation valley of death between science and nano-pharmaceutical product

...to enable the seamless, timely and cost-friendly transfer of nanopharmaceuticals from lab bench to clinical trials by providing the necessary advanced, affordable and easily accessible PHOENIX-OITB.



PHOENIX Concept & Service Strategies

A non-profit, self-sustained, independent legal entity


- enabling a smooth transfer from lab scale to GMP grade product covering all necessary QES, regulatory, and upscaling aspect
- creating an eco-system in the nanomedicine field to foster a thriving economy



PHOENIX Concept & Service Strategies

One-stop Shop

- "SEP" for any end-user with all level of R&D&I activities from lab to market
- Access to R&D&I and manufacturing facilities and services across Europe at fair conditions through SEP
- Reduced costs for production and regulatory compliance
- Harmonized conditions of PQMS for testing, QES characterization, scale-up and GMP production
- Accelerated development stages, thus market entry
- Paving the way for commercial and industrial implementation.



PHOENIX Work Plan


Service portfolio establishment:


5 demo cases covering:

- 3 delivery routes
 - i.v., oral, skin
 - + 1 diagnostic agent

4 nano-pharmaceutical types

- nanocrystals, lipid vesicles, particle conjugates
- + polymeric diagnostic agent








DEMO CASE

Polymer-based diagnostic agent



Topas Therapeutics

DEMO CASE


Polymeric particle conjugates loaded with small peptides




DEMO CASE

Nanocrystals for oral drug delivery











NANOMOL TECHNOLOGIES





DEMO CASE

Nanoliposomes loaded with an enzyme for intravenous administration







DEMO CASE

Antimicrobial nanovesicles for topical administration

PHOENIX Work Plan

Service portfolio establishment:

5 demo cases covering:

- 3 delivery routes
 - i.v., oral, skin
 - + 1 diagnostic agent


4 nano-pharmaceutical types

- nanocrystals, lipid vesicles, particle conjugates
- + polymeric diagnostic agent

Service portfolio validation:

2 pro-bono demo cases covering:

- open call
- any end-user for any service
- all costs covered by PHOENIX project



PHOENIX Open Call

Offering funded services in 4 areas:



Physico-Chemical Characterisation



in vitro Characterisation

ಸ್ತಾ

in vivo Characterisation



Manufacturing

Who can apply?

 Any legal entity (SME, start up or RTO) and research group, based in the European Union or associate countries of H2020

Timeline

- Apply by 28 Feb 2023
- Notice given by 31 Mar 2023
- 2nd stage application due 30 June 2023

All info: https://www.phoenix-oitb.eu/open-call/

PHOENIX Open Call

Offering funded services in 4 areas:



Physico-Chemical Characterisation

- Surface Properties
- Moisture/Dry, Mass
- Size & Distribution
- Structure
- Morphology
- Composition
- Chemical Stability
- Particle concentration
- Drug (API) release kinetics
- Free/Encapsuled API Sterility



in vitro Characterisation

- Composition
- Bioactivity
- Immunocompatibility
- Immunoresponse
- Extraction of targeted cells
- (A)cellular reactivity & cytotoxicity
- Cell viability
- Cel. struct.,
- Uptake & localisation,
- Inflammatory response
- Endocytosis/Exocytosis

- Sensitization & Irritation
- Cytotoxicity
- Genotoxicity
- Nanomechanical prop. of cells & tissues
- Dose metrics
- Microbial evaluation
- Transcriptomics
- Metabolomics
- Proteomics
- Gene expression

PHOENIX Open Call

Offering funded services in 4 areas:



in vivo Characterisation

- Biodistribution
- Hemocompatibility
- Pharmacokinetics
- Pharmacodynamics
- Acute, Sub-acute & Repeated
 Dose systemic toxicity
- Reproductivity toxicity



Manufacturing

- Manufacturing of liquid, semi-solid, solid nanoparticle formulations with a special focus on extended release parenterals
- lipid based formulations and nanovesicles

- Liposomes
- solid lipid nanoparticles
- crystalline nanoparticles,
- polymeric nanoparticles
- inorganic nanoparticles
- On-site lyophilization and fill and finish capabilities.

STATUS

- 10 applicants
 - 4 countries (FR, ES, IT, UK)
 - 6 SMEs

Phoenix-OITB

- improve the European infrastructure and competence in nanopharmaceutical process development, characterisation, quality control and production
- increase of the attractiveness of Europe as a location-of-choice to carry out advanced medical and nano-pharmaceutical research and product development
- improve nano-pharmaceuticals supply capacity and availability of a rich eco-system of related suppliers of products and services



STAY TUNED & FOLLOW OUR PROGRESS



www.phoenix-oitb.eu